Category Archives: Special 301 report

The Trump Executive Order on drug prices: not what was promised nor needed, and contrary to US self interest

Source: Medium Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six page document outlining the draft provisions or objectives of a proposed Presidential Executive Order (EO) on drug prices. She has shared some of … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment

June 2017 Alert: Pressure on countries hiked by US on IP

The US government is stepping up on TRIPS plus pressure through bilateral forums based on a US law that passed under Obama to strengthen IPR enforcement and the 301 process. Countries targeted include India, Indonesia, China, Thailand, Ukraine in Asia … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment

US continue to bully India – Place India again in Special 301 Priority Watch List 2017

Yet again, USTR places India on its Priority Watch List in Special report 301 stating the lack of sufficient measurable improvements to its IP framework that negatively affects U.S. right holders across the world.  It points out that India support … Continue reading

Posted in Sec 3 (d), Special 301 report, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized, USTR, USTR 301 report | Leave a comment

Panel Rejects Eli Lilly Claim Over Canadian Patent Law, Orders Company to Pay Millions in Costs

In the early 1990s, Eli Lilly applied for patent protection in Canada for two chemical compounds, olanzapine and atomoxetine. The company had already obtained patents over the compounds, but asserted that it had evidence to support new uses for the … Continue reading

Posted in Investor state dispute, NAFTA, Special 301 report, Uncategorized, USTR, USTR 301 report | Leave a comment

Indian pharma at odds with US trade group over USTR Priority Watch List

The tug of war continues. Even as the Indian Pharmaceutical Alliance, the domestic drug industry lobby group, has appealed to the US Trade Representative to remove India from its Priority Watch List – the latter includes countries that are alleged … Continue reading

Posted in IP Rights, IPR, IPR policy, Special 301 report, Uncategorized, USTR 301 report | Leave a comment

US continues to keep India on intellectual property priority watch list

By Kritika Suneja, ET Bureau| April 27, 2016 NEW DELHI: India continues to figure in the US’ Priority Watch List that identifies trade barriers to US companies due to intellectual property laws of other countries.

Posted in IPR, Special 301 report, Uncategorized, USTR 301 report | Leave a comment

On IP Protection, USTR Finds Fault With China, India … And Switzerland?

BY WILLIAM NEW, INTELLECTUAL PROPERTY WATCH| April 27, 2016 The Office of the United States Trade Representative (USTR) does not hesitate to add even its closest friends to its annual list of concerns about possible inadequate protection of US intellectual … Continue reading

Posted in IPR, Special 301 report, Uncategorized, USTR 301 report | Leave a comment